Teglarinad

Drug Profile

Teglarinad

Alternative Names: EB-1627; GMX 1777

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LEO Pharma
  • Developer Gemin X Biotechnologies
  • Class Antineoplastics; Guanidines; Pyridines; Small molecules
  • Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Lymphoma; Solid tumours
  • Discontinued Malignant melanoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
  • 17 Aug 2012 Gemin X (now Cephalon) terminates phase I trial in Lymphoma or Solid tumours in USA (NCT00457574)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top